# RASolute 309 (NCT07805954)

> Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07805954
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
- Interventions: daraxonrasib; gemcitabine; nab-paclitaxel; zoldonrasib
- Enrollment: 400
- Primary outcome: Progression free survival (PFS)
- Primary outcome: Overall survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- YouTube: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rasolute-309-nct07805954

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07805954", "email": "<work email>"}; the inbox owner confirms by the emailed link.